v3.26.3
Condensed Consolidated Statements of Changes in Shareholders' Equity - USD ($)
$ in Millions
Total
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive (Loss) Income
Accumulated Surplus
Common shares outstanding, beginning balance (in shares) at Dec. 31, 2024   1,294,580,140      
Balance, beginning of the period at Dec. 31, 2024 $ 11,558 $ 9,634 $ 305 $ (10) $ 1,629
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Exercise of stock options (in shares)   1,190,811      
Exercise of stock options 59 $ 87 (28)    
Stock-based compensation 114   114    
Vesting of restricted share units (in shares)   1,055,597      
Vesting of restricted share units (2) $ 86 (88)    
Issuance of shares related to business acquisition (in shares)   252,257      
Issuance of shares related to business acquisition 0 $ 24 (24)    
Net income (loss) and comprehensive income (loss) for the period (678)     4 (682)
Common shares outstanding, ending balance (in shares) at Mar. 31, 2025   1,297,078,805      
Balance, end of the period at Mar. 31, 2025 11,051 $ 9,831 279 (6) 947
Common shares outstanding, beginning balance (in shares) at Dec. 31, 2024   1,294,580,140      
Balance, beginning of the period at Dec. 31, 2024 11,558 $ 9,634 305 (10) 1,629
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net income (loss) and comprehensive income (loss) for the period 497        
Common shares outstanding, ending balance (in shares) at Sep. 30, 2025   1,301,281,052      
Balance, end of the period at Sep. 30, 2025 12,511 $ 10,123 272 (1) 2,117
Common shares outstanding, beginning balance (in shares) at Mar. 31, 2025   1,297,078,805      
Balance, beginning of the period at Mar. 31, 2025 11,051 $ 9,831 279 (6) 947
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Exercise of stock options (in shares)   1,132,628      
Exercise of stock options 44 $ 68 (24)    
Stock-based compensation 113   113    
Vesting of restricted share units (in shares)   1,156,751      
Vesting of restricted share units (1) $ 86 (87)    
Net income (loss) and comprehensive income (loss) for the period 917     11 906
Common shares outstanding, ending balance (in shares) at Jun. 30, 2025   1,299,368,184      
Balance, end of the period at Jun. 30, 2025 12,124 $ 9,985 281 5 1,853
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Exercise of stock options (in shares)   706,028      
Exercise of stock options 24 $ 34 (10)    
Stock-based compensation 107   107    
Vesting of restricted share units (in shares)   1,206,840      
Vesting of restricted share units (2) $ 104 (106)    
Net income (loss) and comprehensive income (loss) for the period 258     (6) 264
Common shares outstanding, ending balance (in shares) at Sep. 30, 2025   1,301,281,052      
Balance, end of the period at Sep. 30, 2025 12,511 $ 10,123 272 (1) 2,117
Common shares outstanding, beginning balance (in shares) at Dec. 31, 2025   1,303,904,301      
Balance, beginning of the period at Dec. 31, 2025 13,473 $ 10,376 236 1 2,860
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Exercise of stock options (in shares)   202,056      
Exercise of stock options 6 $ 10 (4)    
Stock-based compensation 132   132    
Vesting of restricted share units (in shares)   886,692      
Vesting of restricted share units (3) $ 106 (109)    
Common stock, repurchased (in shares)   (4,214,019)      
Common stock, repurchased (521) $ (521)      
Net income (loss) and comprehensive income (loss) for the period (586)     (5) (581)
Common shares outstanding, ending balance (in shares) at Mar. 31, 2026   1,300,779,030      
Balance, end of the period at Mar. 31, 2026 12,501 $ 9,971 255 (4) 2,279
Common shares outstanding, beginning balance (in shares) at Dec. 31, 2025   1,303,904,301      
Balance, beginning of the period at Dec. 31, 2025 $ 13,473 $ 10,376 236 1 2,860
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Exercise of stock options (in shares) 687,079        
Common stock, repurchased (in shares) (21,145,824)        
Net income (loss) and comprehensive income (loss) for the period $ 1,376        
Common shares outstanding, ending balance (in shares) at Sep. 30, 2026   1,286,382,911      
Balance, end of the period at Sep. 30, 2026 12,749 $ 8,219 293 (6) 4,243
Common shares outstanding, beginning balance (in shares) at Mar. 31, 2026   1,300,779,030      
Balance, beginning of the period at Mar. 31, 2026 12,501 $ 9,971 255 (4) 2,279
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Exercise of stock options (in shares)   112,390      
Exercise of stock options 3 $ 5 (2)    
Stock-based compensation 128   128    
Vesting of restricted share units (in shares)   961,125      
Vesting of restricted share units (2) $ 105 (107)    
Common stock, repurchased (in shares)   (12,645,957)      
Common stock, repurchased (1,445) $ (1,445)      
Net income (loss) and comprehensive income (loss) for the period 1,499     (3) 1,502
Common shares outstanding, ending balance (in shares) at Jun. 30, 2026   1,289,206,588      
Balance, end of the period at Jun. 30, 2026 12,684 $ 8,636 274 (7) 3,781
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Exercise of stock options (in shares)   372,633      
Exercise of stock options 15 $ 22 (7)    
Stock-based compensation 140   140    
Vesting of restricted share units (in shares)   1,089,538      
Vesting of restricted share units (3) $ 111 (114)    
Common stock, repurchased (in shares)   (4,285,848)      
Common stock, repurchased (550) $ (550)      
Net income (loss) and comprehensive income (loss) for the period 463     1 462
Common shares outstanding, ending balance (in shares) at Sep. 30, 2026   1,286,382,911      
Balance, end of the period at Sep. 30, 2026 $ 12,749 $ 8,219 $ 293 $ (6) $ 4,243